Cambridge scientists develop AI-driven 'super test' for prostate cancer

Scientists at EDX Medical Group in Cambridge have developed a groundbreaking 'super test' for prostate cancer, aimed at enhancing screening, diagnosis, and personalized treatment. This innovative test analyzes over 100 clinically validated biomarkers from blood and urine samples using an AI-driven algorithm, achieving a sensitivity and specificity of 96-99%. It addresses a significant gap in current prostate cancer testing, which often relies on fewer than 20 biomarkers and can be unreliable. The test is expected to detect various cancer sub-types and will particularly benefit men aged 45-70, reducing the need for invasive procedures. EDX Medical has filed for patents and aims to seek regulatory approval by the end of 2025. The test represents a potential revolution in prostate cancer management, providing earlier detection and improved risk prediction.